BE2016C014I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C014I2
BE2016C014I2 BE2016C014C BE2016C014C BE2016C014I2 BE 2016C014 I2 BE2016C014 I2 BE 2016C014I2 BE 2016C014 C BE2016C014 C BE 2016C014C BE 2016C014 C BE2016C014 C BE 2016C014C BE 2016C014 I2 BE2016C014 I2 BE 2016C014I2
Authority
BE
Belgium
Application number
BE2016C014C
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of BE2016C014I2 publication Critical patent/BE2016C014I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
BE2016C014C 2004-04-15 2016-04-21 BE2016C014I2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56234004P 2004-04-15 2004-04-15
US56909604P 2004-05-07 2004-05-07
US59940104P 2004-08-06 2004-08-06
US61015904P 2004-09-14 2004-09-14
US61000204P 2004-09-14 2004-09-14
US61000104P 2004-09-14 2004-09-14
US62057304P 2004-10-20 2004-10-20

Publications (1)

Publication Number Publication Date
BE2016C014I2 true BE2016C014I2 (fr) 2024-10-09

Family

ID=34965899

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C014C BE2016C014I2 (fr) 2004-04-15 2016-04-21

Country Status (17)

Country Link
US (9) US8129346B2 (fr)
EP (1) EP1745064B1 (fr)
JP (3) JP5616569B2 (fr)
CN (2) CN102174076A (fr)
AT (1) ATE494298T1 (fr)
AU (1) AU2005238445B2 (fr)
BE (1) BE2016C014I2 (fr)
BR (1) BRPI0509879A (fr)
CA (1) CA2562411A1 (fr)
CY (1) CY1117244T1 (fr)
DE (1) DE602005025750D1 (fr)
DK (1) DK1745064T3 (fr)
IL (3) IL178400A (fr)
PL (1) PL1745064T3 (fr)
PT (1) PT1745064E (fr)
SG (2) SG152239A1 (fr)
WO (1) WO2005105827A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AU2012203602B2 (en) * 2004-04-15 2015-08-27 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
WO2006063154A1 (fr) * 2004-12-07 2006-06-15 Proteolix, Inc. Composition destinee a inhiber le proteasome
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
NZ597545A (en) * 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
JP5734656B2 (ja) * 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
WO2010105363A1 (fr) 2009-03-16 2010-09-23 Andrei Yudin Molécules d'acides aminés cycliques et leurs méthodes de synthèse
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
CA2791651C (fr) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Composes pour inhibition de l'immunoproteasome
EP2555621A4 (fr) 2010-04-07 2014-07-02 Onyx Therapeutics Inc Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin
MX364393B (es) 2012-05-08 2019-04-24 Onyx Therapeutics Inc Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
PL2968555T3 (pl) 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
WO2015009888A2 (fr) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Inhibiteurs du protéasome époxycétones peptidiques en combinaison avec des inhibiteurs de pim kinase pour le traitement de cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
US20160215016A1 (en) * 2013-09-06 2016-07-28 Sandoz Ag Synthesis of peptide epoxy ketones
CA2922210A1 (fr) * 2013-09-06 2015-03-12 Sandoz Ag Synthese stereoselective de diols et de triols par reaction de mannich et utilisation correspondante pour la synthese de carfilzomib
CN104710507B (zh) * 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法
WO2015121769A1 (fr) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Procédé pour la préparation de méthyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phénylalaninate
PT3166933T (pt) * 2014-07-14 2018-12-06 Centrax Int Inc Compostos de epoxicetona para inibição de enzimas
US10329325B2 (en) 2014-09-24 2019-06-25 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
US20160115198A1 (en) 2014-10-27 2016-04-28 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
WO2016088031A1 (fr) 2014-12-02 2016-06-09 Fresenius Kabi Oncology Limited Procédé de purification de carfilzomib
US10301353B2 (en) 2014-12-31 2019-05-28 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016116882A2 (fr) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Nouvelles compositions de carfilzomib
WO2016170544A1 (fr) * 2015-04-22 2016-10-27 Msn Laboratories Private Limited Procédé de préparation de (2s)-n-((s)-1-((s)-4-méthyl-1-((r)-2-méthyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phényléthyl)-2-((s)-2-(2-morpholino acétamido)-4-phénylbutanamido)-4-méthylpentanamide
WO2016170489A1 (fr) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Compositions pharmaceutiques d'un inhibiteur de protéasome
US10364269B2 (en) 2015-05-21 2019-07-30 Laurus Labs Limited Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
JP6961586B2 (ja) 2015-11-11 2021-11-05 ジーランド ファーマ エイ／エス α４β７インテグリンを標的とする環状ペプチド
EP3494126A1 (fr) 2016-08-02 2019-06-12 Synthon BV Procédé de fabrication du carfilzomib
US11078231B2 (en) 2016-09-14 2021-08-03 Fresenius Kabi Oncology Ltd Process for purification of carfilzomib intermediate
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
EP3330260A1 (fr) 2016-12-01 2018-06-06 Enantia, S.L. Procédé pour la préparation d'un intermédiaire pour la synthèse de i.a. carfilzomib
CN106946981B (zh) * 2017-03-08 2020-08-21 南京陵瑞医药科技有限公司 一种四肽环氧丙烷衍生物及其制备方法和用途
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
CN111108125A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN113185575B (zh) * 2021-05-11 2022-07-12 四川大学 一种花生抗氧化多肽及其制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
EP4611798A1 (fr) 2022-11-02 2025-09-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
EP4685151A1 (fr) 2024-07-24 2026-01-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteur du protéasome

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja) 1987-11-21 1989-05-29 Nec Corp 状態監視用情報伝送装置
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
EP1136498A1 (fr) 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérines protéases, notamment de NS3 protéase du virus de l'hépatite c
DE69734832T2 (de) 1996-12-13 2006-08-31 Zymogenetics, Inc., Seattle Zusammensetzungen und verfahren zum stimulieren von knochenwachstum
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6099851A (en) 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
NZ511197A (en) 1998-10-20 2003-08-29 Millenium Pharmaceuticals Inc Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
JP2003528039A (ja) * 1999-10-20 2003-09-24 オステオスクリーン，インコーポレイテッド 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP2301565A1 (fr) 2000-10-12 2011-03-30 ViroLogik GmbH Inhibiteurs du proteasome pour le traitement des infections virales
EP1463719A2 (fr) 2002-01-08 2004-10-06 Eisai Co., Ltd Analogues d'eponemycine et d'epoxomicine et leurs utilisations
WO2003086283A2 (fr) 2002-04-09 2003-10-23 Greenville Hospital System Activite de modulation de metastase d'oligosaccharides hautement sulfates
US20030224469A1 (en) 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8129346B2 (en) * 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
WO2005111009A2 (fr) 2004-05-10 2005-11-24 Proteolix, Inc. Synthese de ceto-epoxydes d'acides amines
ES2510840T3 (es) 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
EP2100899A3 (fr) 2004-10-20 2009-09-30 Proteolix, Inc. Composés pour inhibition d'enzyme
WO2006063154A1 (fr) 2004-12-07 2006-06-15 Proteolix, Inc. Composition destinee a inhiber le proteasome
EP1863513A2 (fr) 2005-03-11 2007-12-12 The University of North Carolina at Chapel Hill Inhibiteurs puissants et spécifiques d'immunoprotéasomes
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
JP4325683B2 (ja) * 2007-02-14 2009-09-02 セイコーエプソン株式会社 画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (fr) 2007-05-10 2008-11-20 Proteolix, Inc. Composés d'inhibition enzymatique
JP5734656B2 (ja) 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы

Also Published As

Publication number Publication date
CN103554222A (zh) 2014-02-05
CA2562411A1 (fr) 2005-11-10
BRPI0509879A (pt) 2007-10-16
US20130324459A1 (en) 2013-12-05
IL178400A (en) 2012-02-29
EP1745064B1 (fr) 2011-01-05
IL178400A0 (en) 2007-02-11
SG152239A1 (en) 2009-05-29
US8207126B2 (en) 2012-06-26
DK1745064T3 (da) 2011-04-11
IL217211A0 (en) 2012-01-31
JP2008501637A (ja) 2008-01-24
US8207125B2 (en) 2012-06-26
US8207297B2 (en) 2012-06-26
CN102174076A (zh) 2011-09-07
US20120094926A1 (en) 2012-04-19
CY1117244T1 (el) 2017-04-05
PT1745064E (pt) 2011-03-23
JP2012041346A (ja) 2012-03-01
DE602005025750D1 (de) 2011-02-17
WO2005105827A2 (fr) 2005-11-10
US20120094929A1 (en) 2012-04-19
EP1745064A2 (fr) 2007-01-24
JP2014012676A (ja) 2014-01-23
US20120101048A1 (en) 2012-04-26
US20080200398A1 (en) 2008-08-21
AU2005238445B2 (en) 2012-05-03
US8207124B2 (en) 2012-06-26
US20120094930A1 (en) 2012-04-19
AU2005238445A1 (en) 2005-11-10
WO2005105827A3 (fr) 2006-03-30
JP5616569B2 (ja) 2014-10-29
IL217210A0 (en) 2012-01-31
SG185306A1 (en) 2012-11-29
HK1097860A1 (en) 2007-07-06
ATE494298T1 (de) 2011-01-15
US20120277146A1 (en) 2012-11-01
US8207127B2 (en) 2012-06-26
PL1745064T3 (pl) 2011-06-30
US20120094928A1 (en) 2012-04-19
US8324174B2 (en) 2012-12-04
US20120101050A1 (en) 2012-04-26
US8129346B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
BE2016C014I2 (fr)
BE2015C063I2 (fr)
BRPI0508002A (fr)
JP2005267569A5 (fr)
JP2005209942A5 (fr)
JP2005009494A5 (fr)
JP2005318332A5 (fr)
JP2005273771A5 (fr)
JP2005295429A5 (fr)
JP2005267835A5 (fr)
JP2004301840A5 (fr)
JP2005245527A5 (fr)
JP2005235892A5 (fr)
JP2005250613A5 (fr)
JP2005276317A5 (fr)
JP2004323009A5 (fr)
JP2005202087A5 (fr)
JP2004306598A5 (fr)
JP2005284710A5 (fr)
JP2005297885A5 (fr)
JP2005216448A5 (fr)
JP2005262442A5 (fr)
JP2005194228A5 (fr)
JP2005247368A5 (fr)
JP2005241789A5 (fr)